<DOC>
	<DOC>NCT02471274</DOC>
	<brief_summary>To evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (PK) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.</brief_summary>
	<brief_title>PK Study of Sotagliflozin in Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Adult male and female subjects ≥18 to ≤70 years of age Body mass index ≥18.0 to ≤36.0 kg/m2, inclusive, at Screening Subjects with mild, moderate, or severe hepatic impairment Control group of matched healthy subjects Willing and able to provide written informed consent Presence of clinically significant physical, laboratory, or ECG findings that may interfere with any aspect of study conduct or interpretation of results Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of sotagliflozin History of any major surgery within 6 months History of renal disease, or significantly abnormal kidney function test Women who are breastfeeding or are planning to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>